hsa-miR-191 Is a Candidate Oncogene Target for Hepatocellular Carcinoma Therapy
Eran Elyakim(Regulus Therapeutics (United States)), Noga Yerushalmi(Regulus Therapeutics (United States)), Avital Dov(Tel Aviv University), Einat Sitbon(Regulus Therapeutics (United States)), Eric G. Marcusson(Ionis Pharmaceuticals (United States)), Ayelet Chajut(Rosetta Genomics (Israel)), Sarit Tabak(Rosetta Genomics (Israel)), C. Frank Bennett(Pennsylvania State University), Alexander Faerman(Regulus Therapeutics (United States)), Liron Belanis(Regulus Therapeutics (United States)), Dalia Cohen(Regulus Therapeutics (United States)), Eve Montia(Regulus Therapeutics (United States))
Cited by 152
Related Papers
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
MicroRNAs accurately identify cancer tissue origin
|Nature Biotechnology|2008|987
Diagnostic Assay Based on hsa-miR-205 Expression Distinguishes Squamous From Nonsquamous Non–Small-Cell Lung Carcinoma
|Journal of Clinical Oncology|2009|410